Evidence map›Paper›PMID 11543678›Full record

ArticleJournal of medicinal chemistry2001

Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking.

H S Kim, D Barak, T K Harden, J L Boyer, K A Jacobson

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 68 citations in OpenAlex.

  1. Advances in nucleotide-based P2Y₁ antagonism: implications for cardiovascular therapeutics.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Demystifying P2YJournal of chemical information and modeling · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

H S KimMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.
D Barak
T K Harden
J L Boyer
K A Jacobson
National Institutes of Health · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Development Of P2Y Receptor LigandsZIADK031116 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$8.9M
P2Y-PURINERGIC RECEPTORSR01GM038213 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HARDEN, T KENDALL · 1987 to 2012
$3.9M
P2T PURINERGIC RECEPTORSR01HL054889 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI BOYER, JOSE L · 2001 to 2004
$1.0M
P2T-PURINERGIC RECEPTORSR29HL054889 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI BOYER, JOSE L · 1995 to 1999
–
Intramural NIH HHS ZIA DK031116NHLBI NIH HHS HL54889NHLBI NIH HHS R01 HL054889NHLBI NIH HHS R29 HL054889NIGMS NIH HHS GM38213NIGMS NIH HHS R01 GM038213
6 · The paper itself

Abstract

The activation of P2Y1 receptors in platelets contributes to platelet aggregation, and selective antagonists are sought as potential antithrombotic agents. We reported (Kim et al. J. Med. Chem. 2000, 43, 746-755) that acyclic analogues of adenine nucleotides, containing two phosphate groups on a symmetrically branched aliphatic chain, attached at the 9-position of adenine, are moderately potent P2Y1 receptor antagonists. In this study we have varied the chain structure, to include asymmetric substitution, olefinic, and cyclopropyl groups. These antagonists inhibited the stimulation of phospholipase C in turkey erythrocyte membranes induced by 30 nM 2-MeS-ADP in the micromolar range. In the series of symmetrically branched aliphatic groups substituted with two phosphate groups, the optimal antagonist potency occurred with the 2-methylpropyl group. A 2-chloro-N(6)-methyladenine derivative, 2-[2-(2-chloro-6-methylaminopurin-9-yl)methyl]propane-1,3-bisoxy(diammoniumphosphate) (7), was a full antagonist at the P2Y1 receptor with an IC(50) value of 0.48 microM. Esterification of one of the phosphate groups or substitution with O-acetyl greatly reduced the antagonist potency at the P2Y1 receptor. Removal of a methylene group of 7 or inclusion of an olefinic or cyclopropyl group also reduced potency. A pair of enantiomeric glycerol derivatives demonstrated a 5-fold stereoselectivity for the S-isomer. Stereoisomerically defined analogues of 7 containing a cyclopropyl group in place of the branched carbon were less potent than 7 as antagonists, with IC(50) values of 2-3 microM. No agonist activity was observed for these analogues. A new rhodopsin-based molecular model of the P2Y1 receptor indicated that the optimal docked orientation of the two monophosphate moieties relative to the adenine N(6) (compared to a rigid, bicyclic analogue) was consistent with the dependence of antagonist potency on chain length. The 3'-phosphate was predicted to occupy a restricted space, deeper in the binding cleft than the 5'-phosphate location. In summary, modification of the flexible spacer chain linking bisphosphate groups to the adenine moiety provided many moderately potent antagonists.

Indexed as

Purinergic P2 Receptor AntagonistsAdenosine DiphosphateAnimalsChromatography, High Pressure LiquidEnzyme ActivationEnzyme InhibitorsErythrocyte MembraneInositol PhosphatesIn Vitro TechniquesMagnetic Resonance SpectroscopyMass SpectrometryModels, MolecularReceptors, Purinergic P2Receptors, Purinergic P2Y1StereoisomerismStructure-Activity RelationshipAdenosine DiphosphateEnzyme InhibitorsInositol PhosphatesPurinergic P2 Receptor AntagonistsReceptors, Purinergic P2Receptors, Purinergic P2Y1Type C Phospholipases

Identifiers

PMID11543678
PMCPMC9370770
OpenAlexW1967907440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.